A5067434091- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Biosimilars and Bioanalytical Methods
- vaccines and immunoinformatics approaches
- CAR-T cell therapy research
- Inhalation and Respiratory Drug Delivery
- SARS-CoV-2 and COVID-19 Research
- RNA Interference and Gene Delivery
- Advanced biosensing and bioanalysis techniques
Roche (Switzerland)
2022-2024
Lung-resident immune cells, spanning both innate and adaptive compartments, preserve the integrity of respiratory barrier, but become pathogenic if dysregulated1. Current in vitro organoid models aim to replicate interactions between alveolar epithelium cells have not yet incorporated lung-specific critical for tissue residency2. Here we address this shortcoming by describing human lung immuno-organoids (LIO) that contain an autologous tissue-resident lymphoid compartment, primarily composed...
Immunogenicity, defined as the ability to provoke an immune response, can be either wanted (i.e., vaccines) or unwanted. The latter refers response protein peptide therapeutics, characterized by production of anti-drug antibodies, which may affect efficacy and/or safety profiles these drugs. Consequently, evaluation risk immunogenicity early in development biotherapeutics is critical importance for defining their and profiles. Here, we describe validate a fit-for-purpose FluoroSpot-based...
Antisense-oligonucleotides (ASOs) are a promising drug modality for the treatment of neurological disorders, but currently established route administration via intrathecal delivery is major limitation to its broader clinical application. An attractive alternative conjugation ASO an antibody that facilitates access central nervous system (CNS) after peripheral application and target engagement at blood–brain barrier, followed by transcytosis. Here, we show diligent conjugate design...
Immunogenicity refers to the ability of a substance, such as therapeutic drug, elicit an immune response. While beneficial in vaccine development, undesirable immunogenicity can compromise safety and efficacy proteins by inducing anti-drug antibodies (ADAs). These ADAs reduce drug bioavailability alter pharmacokinetics, necessitating comprehensive risk assessments starting at early stages development. Given complexity immunogenicity, integrated approach is essential, no single assay...
A critical step in the immunogenicity cascade is attributed to human leukocyte antigen (HLA) II presentation triggering T cell immune responses. The liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based major histocompatibility complex (MHC) II-associated peptide proteomics (MAPPs) assay implemented during preclinical risk assessments identify biotherapeutic-derived epitopes. Although studies indicate that HLA-DP and HLA-DQ alleles are linked immunogenicity, most MAPPs restricted...
Introduction Immunogenicity, the unwanted immune response triggered by therapeutic antibodies, poses significant challenges in biotherapeutic development. This can lead to production of anti-drug potentially compromising efficacy and safety treatments. The internalization antibodies into dendritic cells (DCs) is a critical factor influencing immunogenicity. Using monoclonal with differences non-specific cellular uptake, as tools explore impact on overall risk immunogenicity, this study...
Clinical anti-drug-antibody (ADA) responses represent a substantial obstacle to the development of efficacious therapeutic antibodies. The enhanced ADA production against idiotype (Id) often displayed by cancer immunotherapy antibodies (CitAbs) can lead exposure loss and subsequently affect anti-tumor efficacy cause undesired effects on safety. Thus, contribute prolonged clinical high attrition rates. Most conventional are now human origin or humanized proteins, hence immunologically...